Ivermectin for onchocercal eye disease (river blindness) (Review)

Table 3. Outcome reporting grid (Continued)
Adverse outcomes Dichotomous E (postural
hypotension)
Outcomes not prespecified in the review
Improvement in visual
acuity 2+ lines
Deterioration in visual
acuity 2+ lines
B (Mazotti reaction)
Dichotomous E A E E
Dichotomous E A E E
Glaucoma Dichotomous E E E Reported
Proportion visually
impaired or blind at
end of study
Dichotomous E E E Reported
Adapted from list provided by Paula Williamson at a Cochrane training workshop on selective outcome reporting bias, Edinburgh
March 2009.
Data included in the review
A: States outcome analysed but only reported the P value > 0.05 i.e. NS
B: States outcome analysed but only reported that P value < 0.05
C: Clear that outcome was analysed but insufficient data presented to be included in meta-analysis or full tabulation
D: Clear that outcome was analysed but no results reported
E: Clear that outcome was measured (for example, includes structurally related outcomes) but not necessarily analysed
F: States that outcome was not measured
G: Not mentioned but clinical judgement says likely to have been measured
H: Not mentioned but clinical judgement says unlikely to have been measured
I: Other give details
Ivermectin for onchocercal eye disease (river blindness) (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
16